Principle Health Systems, a mobile diagnostics provider for long-term care, has acquired Telos PGX, a company engaged in pharmacogenetic testing, for an undisclosed sum.
The acquisition is expected to speed up Telos PGX’s mission to enhance healthcare with personalised medication solutions.
Telos PGX is known for its Telos PGX Program, designed to support Skilled Nursing Facilities (SNFs) and improve patient care.
Using advanced pharmacogenetic testing, Telos PGX helps healthcare providers make precise medication decisions, reducing adverse drug reactions and optimising treatment outcomes.
Telos PGX CEO and founder D.J. Hart said: “We are thrilled to join forces with Principle Health Systems.
“This transaction will provide us with the resources and expertise to scale our operations, accelerate innovation, and expand our reach.
“Together, we will transform the future of healthcare and improve the lives of countless patients.”
D.J. Hart will join the leadership team at Principle Health Systems as director of Pharmacogenetic Operations. Hart will use its expertise in SNF to advance personalised medicine.
Principle Health Systems CEO James Dieter said: “Telos PGX’s innovative approach to pharmacogenetic testing aligns perfectly with our vision to deliver advanced healthcare solutions.
“By combining Principle’s experience and resources with Telos’s innovation, we will be able to accelerate the adoption of personalised medicine and improve patient outcomes.”
Telos PGX is a provider of pharmacogenetic testing in the LTC market. By analysing genetic profiles, the company enables healthcare providers to make informed medication decisions, improving patient outcomes and reducing costs.
Principle Health Systems is focused on improving patient outcomes and care quality.
Through partnerships and advanced technology, the company aims to transform healthcare to support patients ageing in place.
In August this year, Principle Health Systems acquired BioStat Imaging, a Dallas-based mobile imaging provider.
The acquisition will help the firm in delivering comprehensive, diagnostic services to the long-term care community.
In January 2023, private investment company Platform Partners completed its investment in the mobile diagnostics provider.
